Objective:Prescribing of antibiotics for viral upper respiratory infections (URIs) remains a pressing public health problem. We sought to reduce inappropriate prescribing of antibiotics for URIs in Mayo Clinic Arizona.Design:Single-center, quasi-experimental, and retrospective cohort studySetting:Emergency medicine and all primary care departmentsMethods:The interventions included sharing baseline prescribing data, education, resources, and quarterly peer comparison reports. Encounters with diagnostic codes for respiratory infections commonly caused by viruses were categorized as Tier 3 (ie, never appropriate to prescribe antibiotics). Our goal was to reduce inappropriate prescribing for Tier 3 encounters by 22% in 2022.Results:Department education was completed by June 2022. The annual antibiotic prescribing rate for Tier 3 encounters was reduced by 29%, from a baseline rate of 23.6% in 2021 to 16.4% in 2022 (P < .001). The posteducation prescribing rate was 13.1%. Repeat respiratory-related healthcare contact within 14 days of Tier 3 encounters did not differ between patients prescribed and not prescribed an antibiotic in all of 2022 (4.7% antibiotic vs 4.2% no antibiotic, P = .595) or during the posteducation period (3.7% vs 4.6%, P = .604).Conclusion:A multi-faceted intervention, which included baseline education, syndrome-specific order panels, resources for symptomatic management, and peer comparison reports, resulted in significant reduction of inappropriate antibiotic prescribing for URIs.
Donor-derived tuberculosis is a rare complication following solid organ transplantation, and tuberculosis screening is not a current transplant prerequisite for most donors. Donor-derived tuberculosis usually presents sooner than reactivation tuberculosis, and the most common finding is fever. We present 3 cases of donor-derived tuberculosis in the recipients of 2 kidneys and 1 liver from the same donor, who presented with unexplained fevers occurring 4–5 weeks after transplantation. Initial antibacterial therapy failed in all 3 patients, leading to further testing, which identified Mycobacterium tuberculosis by culture and molecular studies. All recipients successfully received tuberculosis therapy but had significant morbidity and prolonged hospital stays. Donor-derived tuberculosis should be among the differential diagnoses of unexplained fever in solid organ transplant recipients in the first few months after transplantation. Screening protocols should be implemented for donors with an epidemiologic risk of tuberculosis, with special emphasis on deceased donors.
Vaccination remains a cornerstone of infection prevention in adult solid organ transplant (SOT) recipients, a population at heightened risk for vaccine-preventable diseases due to chronic immunosuppression and comorbidities. Updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (AST IDCOP) and other international bodies emphasize the need for timely and comprehensive vaccination strategies before and after transplantation. This review synthesizes current literature and practice guidelines on vaccination in adult solid organ transplant (SOT) candidates and recipients. Published peer-reviewed studies, clinical trials, and consensus guidelines were evaluated, with emphasis on vaccination timing, safety, immunogenicity, dosing strategies, and serologic response monitoring in the SOT population. Comprehensive vaccination planning before transplantation, combined with appropriate post-transplant booster strategies, remains vital to improving long-term outcomes in SOT recipients. This review provides clinicians with an updated, evidence-based framework for integrating evolving vaccination guidelines into the care of adult transplant patients.
2 November 2026 in American Journal of Health-System Pharmacy
Purpose: Handshake antimicrobial stewardship (HAS) facilitates professional relationship building while ensuring safe and appropriate antimicrobial use. Development of a pharmacist-physician co-led HAS program requires interdisciplinary collaboration and coordination. In this case study, we describe our experience establishing a HAS program across 2 service lines. Summary: A quality improvement framework was used to identify partnering services and program outcome metrics for HAS. Service lines with high antimicrobial utilization and/or limited antimicrobial stewardship contact were identified. Stewardship champions within partner service lines were identified to assist with HAS scheduling, coordination, and socialization. HAS programs were established with the hospital medicine and acute care surgery service lines and executed as scheduled once-weekly face-to-face rounds and review of all patients on systemic antimicrobials. One year post implementation, acceptance of HAS recommendations was greater than 80% for both services. Broad-spectrum antibiotic use decreased, and communication with stewardship pharmacists increased among intervention service lines. Program outcomes were communicated to quality and hospital leadership. Providers expressed high satisfaction with the HAS programs. Conclusion: Creation of an HAS program requires data-informed, interdisciplinary collaboration between pharmacy, antimicrobial stewardship, administration, and partner prescribers and service lines. HAS facilitates stewardship efforts and simultaneously promotes stronger professional relationships with prescribers. Through regular face-to-face interactions with pharmacists via HAS, prescribers incorporate antimicrobial stewardship into daily practice and appreciate antimicrobial stewards as partners in advancing patient care.